Effortless Recombinant Human Macrophage Inflammatory Protein-1 Alpha/ccl3 (human Mip-1α/ccl3) _ 90950es Add To Cart [4bIfhzuW]

Recombinant Human Macrophage Inflammatory Protein-1 alpha (CCL3)

Introducing our premium Recombinant Human Macrophage Inflammatory Protein-1 alpha (CCL3), a crucial component of the immune and inflammatory response system. This high-quality protein, also known as MIP-1 alpha and LD78, belongs to the CC subfamily of chemokines and is closely related to CCL4/MIP-1 beta. With a strong emphasis on purity and biological activity, our CCL3 is a reliable tool for researchers studying immune responses and inflammatory diseases. Key benefits include:

• High Purity: >96% purity by SDS-PAGE and HPLC analyses.
• Biological Activity: Fully active, as demonstrated by chemotaxis bioassays.
• Endotoxin Level: < 1.0 EU per 1 μg by the LAL method.

Product Properties and Specifications

Our Recombinant Human CCL3 is derived from E. coli and is expressed as an alanine 23 to alanine 94 fragment. It has a molecular weight of approximately 7.8 kDa and shares 70% - 74% amino acid sequence identity with mouse, rat, and cotton rat CCL3. This chemokine forms complexes with sulfated proteoglycans and can be detected by ELISA, RIA, and Western blot. Additional properties include:

• Physical Appearance: Sterile filtered white lyophilized powder.
• Source: E.coli-derived Human CCL3, Ala23-Ala94.
• Formulation: Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 100 mM NaCl.

Applications and Benefits

Our Recombinant Human Macrophage Inflammatory Protein-1 alpha (CCL3) is a valuable research tool for studying various hematopoietic cell types, including activated T cells, NK cells, neutrophils, monocytes, immature dendritic cells, and eosinophils. It promotes chemoattraction, adhesion to activated vascular endothelium, and cellular activation, making it a key component in research on immune and inflammatory diseases. Target audience scenarios include:

• Researchers in immunology and inflammation.
• Pharmaceutical and biotech companies developing new treatments.
• Academic institutions conducting cutting-edge research.